These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Role of teicoplanin in the ambulatory treatment of infections in children due to gram-positive microorganisms].
    Author: Debbag R, Paganini H, Gómez S, Casimir L, Stamboulian D.
    Journal: Medicina (B Aires); 2002; 62 Suppl 2():48-51. PubMed ID: 12481489.
    Abstract:
    Infections caused by Gram-positive bacteria remain a major cause of morbidity and mortality. Teicoplanin is a glycopeptide antibiotic with similar spectrum to vancomycin. Easy administration and dosage encourage its use in children, particularly due to its long half-life which allows single daily dose regimens. We evaluated the efficacy of teicoplanin in severe infections in children due to Gram-positive organisms. We retrospectively analyzed 171 children with proven or suspected Gram-positive infection treated with teicoplanin between January 1996 and December 2000. Of them, 166 cases were valuable for clinical assessment. Staphylococcus aureus (72) and coagulase-negative staphylococci (38) were the most frequent pathogens isolated. Osteoarthritis (35) and catheter-related infections (31) were the predominant clinical foci. The cure and improvement rates were 88% (150 patients) and 5% (9 patients) respectively. There were 7 (4%) cases of therapeutic failure. Mean treatment duration was 10 +/- 34.3 days (range: 1-205). Adverse events were registered in 11 patients (6%, 15 adverse events). In this study population, teicoplanin was safe and effective in the ambulatory treatment of severe Gram-positive infections in children.
    [Abstract] [Full Text] [Related] [New Search]